US researchers conducted a series research using recombinant mouse proteins and published a paper in the November 2, 2016, saying that they confirmed that the new drug Verubecestat in the clinical trial phase of Alzheimer's disease (AD) does not bring harmful side effects, and the effect of the drug as agentia is worthy waiting.
The study published in the US medical journal Science Translational Medicine refers, "From the beginning of the experiment that they began investigating 32 patients with varying degrees of Alzheimer's disease, now there are more than 3,000 patients participate in the experiment. The team also launched two comprehensive large-scale clinical trials."
In the treatment, the experts selected the compound Verubecestat developed by the US pharmaceutical company. Verubecestat is able to inhibit the BACEI enzyme and reduce the amount of β-amyloid.
One of the pathological features of Alzheimer's disease (AD) is the presence of amyloid plaques (β-amyloid deposits) in the brain. Such plaques not only severely affect memory, but also have significant influence on protein generation. Although BACEI enzyme inhibitors in the past have a certain effect, it often brings liver dysfunction, neuropathy and other serious side effects.
In this clinical trial, the specialists plan to verify the effectiveness of Verubecestat through three treatment stages. Now they have entered the third test phase and plan to draw the final test conclusions in July, 2017. If the results are good, then Verubecestat will enter market in 2-3 years as new treatment drug. By the way, Flarebio provides you with superior recombinant proteins like recombinant TLR2 at competitive prices.
没有评论:
发表评论